Instrument Inactif

Autres langues Zeltia SA

Actions

ES0184940817

Cours en clôture BME Autres places de cotation
- ^EUR	-

2015	DJ Industrial : Wall Street termine dans le vert une séance volatile	RE
2015	China CITIC Bank : Les valeurs à suivre sur les marchés américains	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alibaba's Singles' Day sales surge 60 percent to $14.3 billion	11/11/15
Alibaba : China consumers to spend more in November 11 'Singles Day' shopping spree - Nielsen	04/11/15
Zeltia : PharmaMar to Present New Studies for YONDELIS® and PM1183 in Ovarian Cancer during ESGO 2015	26/10/15
Zeltia : U.S. FDA Approves YONDELIS® (trabectedin) for Soft Tissue Sarcoma (Liposarcoma or Leiomyosarcoma)	23/10/15
Zeltia : Grupo Zeltia reports 126.8 million euro in net sales (+8.5%) in the first nine months of 2015	21/10/15
Zeltia : Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma	21/09/15
Zeltia : PharmaMar initiates a phase II “Basket” trial for PM1183 in selected advanced solid tumors	17/09/15
Zeltia : PharmaMar opens new affiliate in UK	15/09/15
Zeltia : Pharmaceutical Council Recommends Approval of YONDELIS® (trabectedin) in Japan	01/09/15
Zeltia : PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for APLIDIN® (plitidepsin) in oncology	20/08/15
Zeltia : PharmaMar passes the U.S. FDA manufacturing inspection for YONDELIS® active ingredient	31/07/15
Zeltia : Grupo Zeltia Reports First Half 2015 Financial Results	28/07/15
Zeltia : PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers	23/07/15
Zeltia : GENOMICA and the Foundation for Excellence and Quality in Oncology announce a framework agreement for collaboration in Oncology	22/07/15
Zeltia : PharmaMar initiates the phase III study CORAIL for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer	29/06/15
Zeltia : PharmaMar announces that Janssen´s study shows that trabectedin improves disease control in patients with advanced soft tissue sarcoma	02/06/15
Zeltia : PharmaMar completes patient recruitment of Phase III registration trial (ADMYRE) with APLIDIN® (plitidepsin) in multiple myeloma	01/06/15
Zeltia : PharmaMar finaliza el reclutamiento de pacientes del ensayo de Fase III de registro (ADMYRE) con APLIDIN® (plitidepsin) en mieloma múltiple	01/06/15
Zeltia : Grupo Zeltia Reports First Quarter 2015 Financial Results	27/04/15
Zeltia : PharmaMar to present data on anticancer candidates PM1183 and plitidepsin at the AACR Annual Meeting 2015	14/04/15

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Zeltia SA

Actions

ES0184940817

Autres langues

Filtres